The Role of Intraperitoneal Carboplatin as Consalidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review
[摘要] Background: Epithelial ovarian cancer is the leading causeof death from gynecology malignancy. The aim of this study was to assess therole of intraperitoneal chemotherapy with carboplatin, as a consolidativetreatment, in reducing relapse and increasing survival of patients in advancedepithelial ovarian cancers, as well as evaluation of its toxicity. Methods: This clinical trial wasconducted on 30 patients with epithelial ovarian cancer in stages II-IV inGynecology oncology department in Valiasr University Hospital, Tehran during2005-2010. They were enrolled through non-random sequential selection. Theydivided into 18 cases as the intervention group (receiving intraperitonealchemotherapy) and 12 patients as the control group (with only retrospectivefollow-up). The cases received 3 cycles of 400 mg/m2 intraperitonealcarboplatin every 21 days following intravenous chemotherapy. Mean survival oftwo and five years, progression-free interval, overall survival, relapse,demographic parameters, drug toxicities and pathologic types of cancers werecoded in the two groups and compared using SPSS 14. Results: The mean ages of cases andcontrols were 52.4 ± 8.6 and 55.1 ± 11.5 years. The mean duration ofrelapse-free survival was 13 ± 8.6 months for the cases and 9.5 ± 4.3 monthsfor the control patients (not statistically different, P>0.05). The mean overall survival for cases and controls were39 ± 16.5 and 30.8 ± 16.2 months, respectively (no significant difference, P>0.05). The frequency of drugtoxicities in the cases was 5.6%, and consisted of mild-to-moderate abdominal pain,nausea and vomiting. Conclusion: consolidation therapy withintraperitoneal carboplatin may not increase overall survival, reduce relapserate or decrease mortality, though it does not induce considerable sideeffects.
[发布日期] [发布机构]
[效力级别] [学科分类] 分子生物学,细胞生物学和基因
[关键词] [时效性]